Literature DB >> 12802006

Cost-effectiveness of PET in the diagnosis of Alzheimer disease.

Pamela M McMahon1, Sally S Araki, Eileen A Sandberg, Peter J Neumann, G Scott Gazelle.   

Abstract

PURPOSE: To evaluate the cost-effectiveness of positron emission tomography (PET) in the diagnosis of Alzheimer disease (AD) in community-dwelling patients with mild or moderate dementia who present to specialized AD centers.
MATERIALS AND METHODS: A decision-analytic model was used to compare costs and quality-adjusted life years (QALYs) associated with strategies involving single photon emission computed tomography (SPECT), dynamic susceptibility-weighted contrast material-enhanced magnetic resonance (MR) imaging, and PET as functional imaging adjuncts to the standard clinical work-up. Sensitivity analyses were performed to examine changes in test characteristics, health-related quality-of-life survey instruments, therapeutic effectiveness, and treatment rules.
RESULTS: The use of PET to confirm the results of the standard clinical work-up cost more but yielded fewer benefits than a strategy in which dynamic susceptibility-weighted contrast-enhanced MR imaging was substituted for the typically performed structural computed tomography. This relationship remained stable in scenarios in which standard diagnostic work-up accuracy, drug treatment effectiveness, and version of the Health Utilities Index were altered. Dynamic susceptibility-weighted contrast-enhanced MR imaging cost US dollars 598800 per QALY gained (range, US dollars 74400 to US dollars 1.9 million per QALY), compared with the cost of the standard diagnostic work-up. Treating all patients with dementia was the dominant imaging strategy, except when side effects in patients with non-AD-related dementia were modeled. In all scenarios, SPECT yielded fewer benefits than other strategies at a higher cost.
CONCLUSION: PET may have high diagnostic accuracy, but adding it to the standard diagnostic regimen at AD clinics would yield limited, if any, benefits at very high costs. Copyright RSNA, 2003.

Entities:  

Mesh:

Year:  2003        PMID: 12802006     DOI: 10.1148/radiol.2282020915

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  22 in total

1.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Authors:  Alberto Pupi; Flavio Mariano Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

2.  An integrated health-economic analysis of diagnostic and therapeutic strategies in the treatment of moderate-to-severe obstructive sleep apnea.

Authors:  Jan B Pietzsch; Abigail Garner; Lauren E Cipriano; John H Linehan
Journal:  Sleep       Date:  2011-06-01       Impact factor: 5.849

Review 3.  Health state values for use in the economic evaluation of treatments for Alzheimer's disease.

Authors:  James Shearer; Colin Green; Craig W Ritchie; John P Zajicek
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

4.  Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.

Authors:  S G Mueller; N Schuff; M W Weiner
Journal:  NMR Biomed       Date:  2006-10       Impact factor: 4.044

5.  Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.

Authors:  Pei-Jung Lin; Brittany D'Cruz; Ashley A Leech; Peter J Neumann; Myrlene Sanon Aigbogun; Dorothee Oberdhan; Tara A Lavelle
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

6.  Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS.

Authors:  D Eldon Spackman; Srikanth Kadiyala; Peter J Neumann; David L Veenstra; Sean D Sullivan
Journal:  Curr Alzheimer Res       Date:  2012-11       Impact factor: 3.498

Review 7.  Current and future uses of neuroimaging for cognitively impaired patients.

Authors:  Gary W Small; Susan Y Bookheimer; Paul M Thompson; Greg M Cole; S-C Huang; Vladimir Kepe; Jorge R Barrio
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182

Review 8.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

Review 9.  The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis.

Authors:  S L Bermingham
Journal:  Ont Health Technol Assess Ser       Date:  2014-02-01

Review 10.  Application of pet imaging to diagnosis of Alzheimer's disease and mild cognitive impairment.

Authors:  James M Noble; Nikolaos Scarmeas
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.